In vitro models for the prediction of in vivo performance of oral dosage forms

European Journal of Pharmaceutical Sciences

Volumn 57, Issue 1, 2014, Pages 342-366

  Kostewicz, Edmund S ^a   Abrahamsson, Bertil ^b   Brewster, Marcus ^c   Brouwers, Joachim ^d   Butler, James ^e   Carlert, Sara ^b   Dickinson, Paul A ^f   Dressman, Jennifer ^a   Holm, René ^g   Klein, Sandra ^h   Mann, James ⁱ   McAllister, Mark ^j   Minekus, Mans ^k   Muenster, Uwe ^l   Müllertz, Anette ^m   Verwei, Miriam ^k   Vertzoni, Maria ⁿ   Weitschies, Werner ^h   Augustijns, Patrick ^d  

^a GOETHE UNIVERSITY   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c Janssen Pharmaceutica   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e GLAXOSMITHKLINE   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

^g H LUNDBECK A S   (Denmark)

^h UNIVERSITY OF GREIFSWALD   (Germany)

ⁱ MSD   (United Kingdom)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^k TNO   (Netherlands)

^l BAYER PHARMA AG   (Germany)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

Biorelevant; In vitro evaluation; In vivo biopharmaceutical performance; Innovative Medicines Initiative (IMI); Oral Biopharmaceutical Tools (OrBiTo); Oral drug formulations

Indexed keywords

ALBENDAZOLE; AMPRENAVIR; BILE ACID; CELECOXIB; CINNARIZINE; CYCLODEXTRIN; DANAZOL; DICLOFENAC; DIPYRIDAMOLE; EXCIPIENT; GELUCIRE; KETOCONAZOLE; LOVIRIDE; MONTELUKAST; OCTANOL; PROPRANOLOL; SAQUINAVIR; DRUG; DRUG DOSAGE FORM;

CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; GASTROINTESTINAL MOTILITY; HUMAN; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; NONHUMAN; PRECIPITATION; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SIMULATION; TABLET DISINTEGRATION; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; INTESTINE; INTESTINE ABSORPTION; MEDICAL LITERATURE; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHARMACEUTICS; PHARMACOKINETICS; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; DOSAGE FORMS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOPOEIAS AS TOPIC; SOLUBILITY;

EID: 84899628845     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.024     Document Type: Review

References (232)

1. B. Abrahamsson, M. Alpsten, B. Bake, A. Larsson, and J. Sjögren In vitro and in vivo erosion of two different hydrophilic gel matrix tablets Eur. J. Pharm. Biopharm. 46 1998 69 75 (Pubitemid 29168537)
2. B. Abrahamsson, T. Albery, A. Eriksson, I. Gustafsson, and M. Sjöberg Food effects on tablet disintegration Eur. J. Pharm. Sci. 22 2004 165 172 (Pubitemid 38668681)
3. B. Abrahamsson, A. Pal, M. Sjöberg, M. Carlsson, E. Laurell, and J.G. Brasseur A novel in vitro and numerical analysis of shear-induced drug release from extended-release tablets in the fed stomach Pharm. Res. 22 2005 1215 1226 (Pubitemid 41176025)
4. B. Ameer, M. Divoll, D.R. Abernethy, D.J. Greenblatt, and L. Shargel Absolute and relative bioavailability of oral acetaminophen preparations J. Pharm. Sci. 72 1983 955 958 (Pubitemid 13040661)
5. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
6. M.U. Anby, H.D. Williams, M.P. McIntosh, H. Benameur, G.A. Edwards, C.W. Pouton, and C.J. Porter Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems Mol. Pharm. 9 2012 2063 2079
7. S. Aoki, K. Uesugi, K. Tatsuishi, H. Ozawa, and M. Kayano Evaluation of the correlation between in vivo and in vitro release of phenylpropanolamine HCl from controlled-release tablets Int. J. Pharm. 85 1992 65 73
8. S. Aoki, H. Ando, K. Tatsuishi, K. Uesugi, and H. Ozawa Determination of the mechanical impact force in the in vitro dissolution test and evaluation of the correlation between in vivo and in vitro release Int. J. Pharm. 95 1993 67 75 (Pubitemid 23203137)
9. M. Armand, P. Borel, C. Dubois, M. Senft, J. Peyrot, J. Salducci, H. Lafont, and D. Lairon Characterization of emulsions and lipolysis of dietary lipids in the human stomach Am. J. Physiol. 266 1994 G372 G381
10. Y.E. Arnold, G. Imanidis, and M.T. Kuentz Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model J. Pharm. Pharmacol. 63 2011 333 341
11. J. Arrowsmith Trial watch: phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
12. J. Arrowsmith Trial watch: Phase II failures: 2008-2010 Nat. Rev. Drug. Discov. 10 2011 328 329
13. A. Astashkina, B. Mann, and D.W. Grainger A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity Pharmacol. Ther. 134 2012 82 106
14. G. Bai, P.M. Armenante, R.V. Plank, M. Gentzler, K. Ford, and P. Harmon Hydrodynamic investigation of USP dissolution test apparatus II J. Pharm. Sci. 96 2007 2327 2349 (Pubitemid 47477890)
15. J.L. Baxter, J. Kukura, and F.J. Muzzio Hydrodynamics-induced variability in the USP apparatus II dissolution test Int. J. Pharm. 292 2005 17 28 (Pubitemid 40255785)
16. J.L. Baxter, J. Kukura, and F.J. Muzzio Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system AAPS J. 7 2005 E857 E864
17. A. Beig, J.M. Miller, and A. Dahan Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption Eur. J. Pharm. Biopharm. 81 2012 386 391
18. J. Bevernage, J. Brouwers, P. Annaert, and P. Augustijns Drug precipitation-permeation interplay: supersaturation in an absorptive environment Eur. J. Pharm. Biopharm. 82 2012 424 428
19. J. Bevernage, J. Brouwers, M.E. Brewster, and P. Augustijns Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues Int. J. Pharm. 453 2013 25 35
20. S.N. Bhattachar, E.J. Perkins, J.S. Tan, and L.J. Burns Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, TM simulations to predict absorption J. Pharm. Sci. 100 2011 4756 4765
21. S. Blanquet, E. Zeijdner, E. Beyssac, J.-P. Meunier, S. Denis, R. Havenaar, and M. Alric A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions Pharm. Res. 21 2004 585 591 (Pubitemid 38457280)
22. J. Brouwers, J. Tack, F. Lammert, and P. Augustijns Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir J. Pharm. Sci. 95 2006 372 383 (Pubitemid 43241979)
23. J. Brouwers, M.E. Brewster, and P. Augustijns Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98 2009 2549 2572
24. J. Brouwers, B. Anneveld, G.-J. Goudappel, G. Duchateau, P. Annaert, P. Augustijns, and E. Zeijdner Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system Eur. J. Pharm. Biopharm. 77 2011 313 319
25. C.K. Brown, H.D. Friedel, A.R. Barker, L.F. Buhse, S. Keitel, T.L. Cecil, J. Kraemer, J.M. Morris, C. Reppas, M.P. Stickelmeyer, C. Yomota, and V.P. Shah FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms AAPS PharmSciTech 12 2011 782 794
26. P. Buch, P. Langguth, M. Kataoka, and S. Yamashita IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system J. Pharm. Sci. 98 2009 2001 2009
27. S.R. Carino, D.C. Sperry, and M. Hawley Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model J. Pharm. Sci. 95 2006 116 125
28. S.R. Carino, D.C. Sperry, and M. Hawley Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model J. Pharm. Sci. 99 2010 3923 3930
29. S. Carlert, A. Pålsson, G. Hanisch, C. von Corswant, C. Nilsson, L. Lindfors, H. Lennernäs, and B. Abrahamsson Predicting intestinal precipitation - a case example for a basic BCS class II drug Pharm. Res. 27 2010 2119 2130
30. F. Carriere, J.A. Barrowman, R. Verger, and R. Laugier Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans Gastroenterology 105 1993 876 888 (Pubitemid 23249500)
31. N. Castela-Papin, S. Cai, J. Vatier, F. Keller, C.H. Souleau, and R. Farinotti Drug interactions with diosmectite: a study using the artificial stomach-duodenum model Int. J. Pharm. 182 1999 111 119 (Pubitemid 29229799)
32. Center for Drug Evaluation and Research, 2008. Guidance for Industry Orally Disintegrating Tablets.
33. Center for Drug Evaluation and Research, 2013. Drug Innovation - New Molecular Entity Approvals for 2012. < http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm >.
34. L. Chen, G. Hébrard, E. Beyssac, S. Denis, and M. Subirade In vitro study of the release properties of soy-zein protein microspheres with a dynamic artificial digestive system J. Agric. Food Chem. 58 2010 9861 9867
35. A. Christiansen, T. Backensfeld, and W. Weitschies Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes Eur. J. Pharm. Sci. 41 2010 376 382
36. S. Clarysse, J. Tack, F. Lammert, G. Duchateau, C. Reppas, and P. Augustijns Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states J. Pharm. Sci. 98 2009 1177 1192
37. E.T. Cole, R.A. Scott, D. Cade, A.L. Connor, and I.R. Wilding In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules Pharm. Res. 21 2004 793 798 (Pubitemid 39011302)
38. J.F. Cuiné, W.N. Charman, C.W. Pouton, G.A. Edwards, and C.J.H. Porter Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs Pharm. Res. 24 2007 748 757 (Pubitemid 46411963)
39. J.F. Cuiné, C.L. McEvoy, W.N. Charman, C.W. Pouton, G.A. Edwards, H. Benameur, and C.J.H. Porter Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 97 2008 995 1012 (Pubitemid 351293898)
40. W. Curatolo, J.A. Nightingale, and S.M. Herbig Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu Pharm. Res. 26 2009 1419 1431
41. A. Dahan, and A. Hoffman The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats Eur. J. Pharm. Biopharm. 67 2007 96 105 (Pubitemid 46991342)
42. D.M. D'Arcy, O.I. Corrigan, and A.M. Healy Hydrodynamic simulation (computational fluid dynamics) of asymmetrically positioned tablets in the paddle dissolution apparatus: impact on dissolution rate and variability J. Pharm. Pharmacol. 57 2005 1243 1250 (Pubitemid 41545889)
43. E. Déat, S. Blanquet-Diot, J.-F. Jarrige, S. Denis, E. Beyssac, and M. Alric Combining the dynamic TNO-gastrointestinal tract system with a Caco-2 cell culture model: application to the assessment of lycopene and alpha-tocopherol bioavailability from a whole food J. Agric. Food Chem. 57 2009 11314 11320
44. A. Diakidou, M. Vertzoni, K. Goumas, E. Söderlind, B. Abrahamsson, J. Dressman, and C. Reppas Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults Pharm. Res. 26 2009 2141 2151
45. P.A. Dickinson, R. Abu Rmaileh, L. Ashworth, R.A. Barker, W.M. Burke, C.M. Patterson, N. Stainforth, and M. Yasin An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs AAPS J. 14 2012 196 205
46. S. Diebold, and J. Dressman Hydrodynamik kompendialer Lösungsgeschwindigkeits-Testapparaturen Pharm. Ind. 63 2001 94 104
47. Diebold S, 2006. Physiological Parameters Relevant to Dissolution Testing: Hydrodynamic Considerations in Pharmaceutical Dissolution Testing, Taylor and Francis (ISBN 0-8247-5467-0) New York, USA, pp. 127-191.
48. G.A. Digenis, E.P. Sandefer, R.C. Page, W.J. Doll, T.B. Gold, and N.B. Darwazeh Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture Pharm. Res. 17 2000 572 582 (Pubitemid 30416395)
49. M. Divoll, D.J. Greenblatt, B. Ameer, and D.R. Abernethy Effect of food on acetaminophen absorption in young and elderly subjects J. Clin. Pharmacol. 22 1982 571 576 (Pubitemid 13170121)
50. J.B. Dressman, and J. Krämer Pharmaceutical Dissolution Testing 2005 Taylor & Francis
51. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res. 15 1998 11 22 (Pubitemid 28080861)
52. J.W. Eaton, D. Tran, W.W. Hauck, and E.S. Stippler Development of a performance verification test for USP apparatus 4 Pharm. Res. 29 2012 345 351
53. M. Erceg, M. Vertzoni, H. Cerić, M. Dumić, B. Cetina-Čižmek, and C. Reppas In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt Eur. J. Pharm. Biopharm. 80 2012 402 409
54. European Medical Agency, 2010. Committee for Medicinal Products for Human Use: Guideline on the Investigation of Bioequivalence (accessed 05.12.12).
55. J.B. Fang, V.K. Robertson, A. Rawat, T. Flick, Z.J. Tang, N.S. Cauchon, and J.S. McElvain Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development Mol. Pharm. 7 2010 1466 1477
56. D.G. Fatouros, F.S. Nielsen, D. Douroumis, L.J. Hadjileontiadis, and A. Mullertz In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks Eur. J. Pharm. Biopharm. 69 2008 887 898
57. S. Fernandez, V. Jannin, J.-D. Rodier, N. Ritter, B. Mahler, and F. Carrière Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain glycerides and PEG esters Biochim. Biophys. Acta 1771 2007 633 640 (Pubitemid 46670793)
58. S. Fernandez, S. Chevrier, N. Ritter, B. Mahler, F. Demarne, F. Carrière, and V. Jannin In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14 Pharm. Res. 26 2009 1901 1910
59. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, and A. Karim Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications Clin. Pharmacokinet. 36 1999 233 254 (Pubitemid 29178760)
60. Food and Drug Administration, 2009. FDA Guidance: Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System.
61. N. Fotaki, and M. Vertzoni Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations - Opus Open Drug Deliv. J. 2010 2 13
62. N. Fotaki, M. Symillides, and C. Reppas In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis Eur. J. Pharm. Sci. 24 2005 115 122 (Pubitemid 40051294)
63. N. Fotaki, M. Symillides, and C. Reppas Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration Eur. J. Pharm. Sci. 26 2005 324 333 (Pubitemid 41278638)
64. N. Fotaki, A. Aivaliotis, J. Butler, J. Dressman, M. Fischbach, J. Hempenstall, S. Klein, and C. Reppas A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations Eur. J. Pharm. Biopharm. 73 2009 115 120
65. K.J. Frank, K.M. Rosenblatt, U. Westedt, P. Hölig, J. Rosenberg, M. Mägerlein, G. Fricker, and M. Brandl Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement Int. J. Pharm. 437 2012 288 293
66. E. Galia, E. Nicolaides, D. Hörter, R. Löbenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705 (Pubitemid 28275645)
67. E. Galia, J. Horton, and J.B. Dressman Albendazole generics - a comparative in vitro study Pharm. Res. 16 1999 1871 1875 (Pubitemid 30040704)
68. G. Garbacz, R.-S. Wedemeyer, S. Nagel, T. Giessmann, H. Mönnikes, C.G. Wilson, W. Siegmund, and W. Weitschies Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses Eur. J. Pharm. Biopharm. 70 2008 421 428
69. G. Garbacz, B. Golke, R.-S. Wedemeyer, M. Axell, E. Söderlind, B. Abrahamsson, and W. Weitschies Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses Eur. J. Pharm. Sci. 38 2009 147 155
70. G. Garbacz, S. Klein, and W. Weitschies A biorelevant dissolution stress test device - background and experiences Expert Opin. Drug Deliv. 7 2010 1251 1261
71. Y. Gargouri, G. Pieroni, C. Riviere, J.F. Sauniere, P.A. Lowe, L. Sarda, and R. Verger Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions Gastroenterology 91 1986 919 925 (Pubitemid 16014599)
72. M.J. Ginski, and J.E. Polli Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system Int. J. Pharm. 177 1999 117 125 (Pubitemid 29067432)
73. GMP Guideline Quality of Modified Release Products (A) Oral Solid Dosage Forms (B) Transdermal Dosage Forms Section I (Quality) CPMP/QWP/604/96, 2013. < http://www.gmp-compliance.org/eca-guideline-3502.html >.
74. K. Goodman, L.A. Hodges, J. Band, H.N.E. Stevens, W. Weitschies, and C.G. Wilson Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy Eur. J. Pharm. Biopharm. 74 2010 84 92
75. V. Gray, G. Kelly, M. Xia, C. Butler, S. Thomas, and S. Mayock The science of USP 1 and 2 dissolution: present challenges and future relevance Pharm. Res. 26 2009 1289 1302
76. P. Gribbon, and A. Sewing High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10 2005 17 22 (Pubitemid 40164815)
77. J.S. Grundy, and R.T. Foster The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties Clin. Pharmacokinet. 30 1996 28 51 (Pubitemid 26030419)
78. C.-H. Gu, D. Rao, R.B. Gandhi, J. Hilden, and K. Raghavan Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility J. Pharm. Sci. 94 2005 199 208 (Pubitemid 40116383)
79. H.R. Guzmán, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.-P. Moreau, O. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 96 2007 2686 2702 (Pubitemid 47597818)
80. M.M. Hann, and G.M. Keserü Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discov. 11 2012 355 365
81. A.-K. Haraldsson, J. Veide, T. Andlid, M.L. Alminger, and A.-S. Sandberg Degradation of phytate by high-phytase Saccharomyces cerevisiae strains during simulated gastrointestinal digestion J. Agric. Food Chem. 53 2005 5438 5444 (Pubitemid 40994858)
82. L. Hendeles, P. Wubbena, and M. Weinberger Food-induced dose dumping of once-a-day theophylline Lancet 2 1984 1471 (Pubitemid 15175153)
83. Home | IMI - Innovative Medicines Initiative, 2013. < http://www.imi.europa.eu/#&panel1-2 >.
84. ICH Expert Working Group, 2009. ICH Harmonised Tripartite Guideline, Pharmaceutical Development Q8 (R2), Current Step 4 Version.
85. K. Ishii, Y. Saitou, R. Yamada, S. Itai, and M. Nemoto Novel approach for determination of correlation between in vivo and in vitro dissolution using the optimization technique Chem. Pharm. Bull. 44 1996 1550 1555 (Pubitemid 26301507)
86. E. Jantratid, N. Janssen, H. Chokshi, K. Tang, and J.B. Dressman Designing biorelevant dissolution tests for lipid formulations: case example - lipid suspension of RZ-50 Eur. J. Pharm. Biopharm. 69 2008 776 785
87. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
88. E. Jantratid, V. De Maio, E. Ronda, V. Mattavelli, M. Vertzoni, and J.B. Dressman Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form Eur. J. Pharm. Sci. 37 2009 434 441
89. M. Kakhi Classification of the flow regimes in the flow-through cell Eur. J. Pharm. Sci. 37 2009 531 544
90. L. Kalantzi, B. Polentarutti, T. Albery, D. Laitmer, B. Abrahamsson, J. Dressman, and C. Reppas The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels Int. J. Pharm. 296 2005 87 93 (Pubitemid 40693376)
91. L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J.B. Dressman, and C. Reppas Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies Pharm. Res. 23 2006 165 176 (Pubitemid 43214673)
92. L. Kalantzi, R. Page, E. Nicolaides, G. Digenis, and C. Reppas In vitro methods can forecast the effects of intragastric residence on dosage form performance Eur. J. Pharm. Sci. 33 2008 445 451
93. M. Kataoka, Y. Masaoka, Y. Yamazaki, T. Sakane, H. Sezaki, and S. Yamashita In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs Pharm. Res. 20 2003 1674 1680 (Pubitemid 37268286)
94. M. Kataoka, Y. Masaoka, S. Sakuma, and S. Yamashita Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system J. Pharm. Sci. 95 2006 2051 2061 (Pubitemid 44433034)
95. M. Kataoka, T. Yokoyama, Y. Masaoka, S. Sakuma, and S. Yamashita Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation Eur. J. Pharm. Sci. 44 2011 544 551
96. M. Kataoka, K. Sugano, C. da Costa Mathews, J.W. Wong, K.L. Jones, Y. Masaoka, S. Sakuma, and S. Yamashita Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development Pharm. Res. 29 2012 1485 1494
97. A.M. Kaukonen, B.J. Boyd, W.N. Charman, and C.J.H. Porter Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids Pharm. Res. 21 2004 254 260 (Pubitemid 38221970)
98. K. Kelly, B. O'Mahony, B. Lindsay, T. Jones, T.J. Grattan, A. Rostami-Hodjegan, H.N.E. Stevens, and C.G. Wilson Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy Pharm. Res. 20 2003 1668 1673 (Pubitemid 37268285)
99. S.M. Khamanga, and R.B. Walker Evaluation of rate of swelling and erosion of verapamil (VRP) sustained-release matrix tablets Drug Dev. Ind. Pharm. 32 2006 1139 1148 (Pubitemid 44721728)
100. Klein, S., 2009. Predicting Food Effects on Drug Release from Extended-release Oral Dosage forms Containing a Narrow Therapeutic Index Drug.
101. S. Klein, and J. Dressman Comparison of drug release from metoprolol modified release dosage.pdf tutorial-metoprolol Dissolut. Technol. 13 2006 6 12
102. S. Klein, and V.P. Shah A standardized mini paddle apparatus as an alternative to the standard paddle AAPS PharmSciTech 9 2008 1179 1184
103. S. Klein, J. Stein, and J. Dressman Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model J. Pharm. Pharmacol. 57 2005 709 719 (Pubitemid 40694878)
104. S. Klein, M.W. Rudolph, B. Skalsky, H.-U. Petereit, and J.B. Dressman Use of the BioDis to generate a physiologically relevant IVIVC J. Control. Release 130 2008 216 219
105. S. Klein, G. Garbacz, M. Pišlar, I. Locatelli, C. Liu, W. Weitschies, W. Siegmund, A. Mrhar, and M. Bogataj The role of individual gastric emptying of pellets in the prediction of diclofenac in vivo dissolution J. Control. Release 2013
106. Kloefer, B., van Hoogevest, P., Moloney, R., Kuentz, M., Mathew, L.S.L., Dressman, J., 2010. Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FaSSIF and FeSSIF. In: SIF Powder References: How It's Been Used to Make Biorelevant Media. Dissolution Technologies, pp. 6-13.
107. M. Kobayashi, N. Sada, M. Sugawara, K. Iseki, and K. Miyazaki Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract Int. J. Pharm. 221 2001 87 94 (Pubitemid 32524038)
108. I. Kola The state of innovation in drug development Clin. Pharmacol. Ther. 83 2008 227 230
109. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
110. F. Kong, and R.P. Singh A human gastric simulator (HGS) to study food digestion in human stomach J. Food Sci. 75 2010 E627 E635
111. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51 (Pubitemid 38195327)
112. C. Krul, A. Luiten-Schuite, R. Baandagger, H. Verhagen, G. Mohn, V. Feron, and R. Havenaar Application of a dynamic in vitro gastrointestinal tract model to study the availability of food mutagens, using heterocyclic aromatic amines as model compounds Food Chem. Toxicol. 38 2000 783 792 (Pubitemid 30628873)
113. A. Larsen, R. Holm, M.L. Pedersen, and A. Müllertz Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis Pharm. Res. 25 2008 2769 2777
114. A.T. Larsen, P. Sassene, and A. Müllertz In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems Int. J. Pharm. 417 2011 245 255
115. Y. Li, and D.J. McClements Inhibition of lipase-catalyzed hydrolysis of emulsified triglyceride oils by low-molecular weight surfactants under simulated gastrointestinal conditions Eur. J. Pharm. Biopharm. 79 2011 423 431
116. J. Li, L. Yang, S.M. Ferguson, T.J. Hudson, S. Watanabe, M. Katsuma, and J.A. Fix In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III AAPS PharmSciTech 3 2002 E33
117. M.A. Lila, D.M. Ribnicky, L.E. Rojo, P. Rojas-Silva, A. Oren, R. Havenaar, E.M. Janle, I. Raskin, G.G. Yousef, and M.H. Grace Complementary approaches to gauge the bioavailability and distribution of ingested berry polyphenolics J. Agric. Food Chem. 2011
118. A. Lindahl, A.L. Ungell, L. Knutson, and H. Lennernäs Characterization of fluids from the stomach and proximal jejunum in men and women Pharm. Res. 14 1997 497 502 (Pubitemid 27205011)
119. L. Lindfors, S. Forssén, J. Westergren, and U. Olsson Nucleation and crystal growth in supersaturated solutions of a model drug J. Colloid Interface Sci. 325 2008 404 413
120. M. Lobell, M. Hendrix, B. Hinzen, J. Keldenich, H. Meier, C. Schmeck, R. Schohe-Loop, T. Wunberg, and A. Hillisch In silico ADMET traffic lights as a tool for the prioritization of HTS hits ChemMedChem 1 2006 1229 1236 (Pubitemid 44786929)
121. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes J. Pharm. Pharmacol. 63 2011 1119 1135
122. H. Malinowski, P. Marroum, V.R. Uppoor, W. Gillespie, H.Y. Ahn, P. Lockwood, J. Henderson, R. Baweja, M. Hossain, N. Fleischer, L. Tillman, A. Hussain, V. Shah, A. Dorantes, R. Zhu, H. Sun, K. Kumi, S. Machado, V. Tammara, T.E. Ong-Chen, H. Mahayni, L. Lesko, and R. Williams Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations Adv. Exp. Med. Biol. 423 1997 269 288 (Pubitemid 27347212)
123. J. Mann, and S. Pygall A formulation case study comparing the dynamic gastric model with conventional dissolution methods Dissolut. Technol. 19 4 2012 14 19 < http://www.dissolutiontech.com/DTresour/201211Articles/DT201211-A02. pdf >
124. L. Marciani, P.A. Gowland, R.C. Spiller, P. Manoj, R.J. Moore, P. Young, S. Al-Sahab, D. Bush, J. Wright, and A.J. Fillery-Travis Gastric response to increased meal viscosity assessed by echo-planar magnetic resonance imaging in humans J. Nutr. 130 2000 122 127 (Pubitemid 30032841)
125. L. Marciani, P.A. Gowland, A. Fillery-Travis, P. Manoj, J. Wright, A. Smith, P. Young, R. Moore, and R.C. Spiller Assessment of antral grinding of a model solid meal with echo-planar imaging Am. J. Physiol. Gastrointest. Liver Physiol. 280 2001 G844 G849
126. L. Marciani, P.A. Gowland, R.C. Spiller, P. Manoj, R.J. Moore, P. Young, and A.J. Fillery-Travis Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI Am. J. Physiol. Gastrointest. Liver Physiol. 280 2001 G1227 G1233
127. L. Marciani, M. Wickham, B.p. Hills, J. Wright, D. Bush, R. Faulks, A. Fillery-Travis, R.c. Spiller, and P.A. Gowl Intragastric oil-in-water emulsion fat fraction measured using inversion recovery echo-planar magnetic resonance imaging J. Food Sci. 69 2004 E290 E296
128. M. McAllister Dynamic dissolution: a step closer to predictive dissolution testing? Mol. Pharm. 7 2010 1374 1387
129. L.G. McCarthy, C. Kosiol, A.M. Healy, G. Bradley, J.C. Sexton, and O.I. Corrigan Simulating the hydrodynamic conditions in the United States Pharmacopeia paddle dissolution apparatus AAPS PharmSciTech 4 2003 E22
130. Measuring the Return from Pharmaceutical Innovation 2012 - Deloitte UK Centre for Health Solutions|Deloitte, UK, 2013. < http://www.twylah.com/ Deloitte/tweets/275996178636754945 >.
131. R. Mellaerts, R. Mols, P. Kayaert, P. Annaert, J. Van Humbeeck, G. Van den Mooter, J.A. Martens, and P. Augustijns Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport Int. J. Pharm. 357 2008 169 179
132. A. Mercuri, A. Lo Curto, M. Wickham, D. Craig, and S. Barker Dynamic gastric model (DGM): a novel in vitro apparatus to assess the impact of gastric digestion on the droplet size of self-emulsifying drug-delivery systems J Pharm. Pharmacol. 60 2008 A2
133. A. Mercuri, A. Passalacqua, M.S.J. Wickham, R.M. Faulks, D.Q.M. Craig, and S.A. Barker The effect of composition and gastric conditions on the self-emulsification process of ibuprofen-loaded self-emulsifying drug delivery systems: a microscopic and dynamic gastric model study Pharm. Res. 28 2011 1540 1551
134. N. Miled, S. Canaan, L. Dupuis, A. Roussel, M. Rivière, F. Carrière, A. de Caro, C. Cambillau, and R. Verger Digestive lipases: from three-dimensional structure to physiology Biochimie 82 2000 973 986
135. J.M. Miller, and A. Dahan Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation Int. J. Pharm. 430 2012 388 391
136. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T.B. Borchardt, G.E. Amidon, G.L. Amidon, and A. Dahan The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharm. 8 2011 1848 1856
137. M. Minekus, P. Marteau, R. Havenaar, and J.H. Huis in 't Veld A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine ATLA. Alternat. Lab. Anim. 23 1995 197 209
138. M. Minekus, M. Smeets-Peeters, A. Bernalier, S. Marol-Bonnin, R. Havenaar, P. Marteau, M. Alric, G. Fonty, and J.H. Huis in't Veld A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products Appl. Microbiol. Biotechnol. 53 1999 108 114 (Pubitemid 30120182)
139. M. Minekus, M. Jelier, J.-Z. Xiao, S. Kondo, K. Iwatsuki, S. Kokubo, M. Bos, B. Dunnewind, and R. Havenaar Effect of partially hydrolyzed guar gum (PHGG) on the bioaccessibility of fat and cholesterol Biosci. Biotechnol. Biochem. 69 2005 932 938 (Pubitemid 41006965)
140. J.O. Miners, K.M. Knights, J.B. Houston, and P.I. Mackenzie In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises Biochem. Pharmacol. 71 2006 1531 1539
141. Mirza, T., Joshi, Y., Vivilecchia, R., 2013. Evaluation of Dissolution Hydrodynamics in the USP, Peak™ and Flat-bottom Vessels Using Different Solubility Drugs|ResearchGate. < http://www.researchgate.net/publication/ 228485312-Evaluation-of-dissolution-hydrodynamics-in-the-USP-Peak-and-flat- bottom-vessels-using-different-solubility-drugs >.
142. S. Missaghi, and R. Fassihi Release characterization of dimenhydrinate from an eroding and swelling matrix: selection of appropriate dissolution apparatus Int. J. Pharm. 293 2005 35 42 (Pubitemid 40381078)
143. K. Mohsin Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion AAPS PharmSciTech 13 2012 637 646
144. J.G. Moore, P.E. Christian, J.A. Brown, C. Brophy, F. Datz, A. Taylor, and N. Alazraki Influence of meal weight and caloric content on gastric emptying of meals in man Dig. Dis. Sci. 29 1984 513 519 (Pubitemid 14075346)
145. W.H. Moos, G.D. Green, and M.R. Pavia Recent advances in the generation of molecular diversity James A. Bristol, Annual Reports in Medicinal Chemistry 1993 Academic Press 315 324 (Chapter 33)
146. S.A. Motz, U.F. Schaefer, S. Balbach, T. Eichinger, and C.-M. Lehr Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell Eur. J. Pharm. Biopharm. 66 2007 286 295 (Pubitemid 46654772)
147. TM for the prediction of in vivo performance J. Appl. Therap. Res. 6 2006 15
148. New Drug Approvals, 2013. < http://www.drugs.com/newdrugs.html >.
149. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388 (Pubitemid 32595828)
150. S. Nury, G. Piéroni, C. Rivière, Y. Gargouri, A. Bois, and R. Verger Lipase kinetics at the triacylglycerol-water interface using surface tension measurements Chem. Phys. Lipids 45 1987 27 37
151. A. Okumu, M. DiMaso, and R. Löbenberg Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug Pharm. Res. 25 2008 2778 2785
152. A. Okumu, M. DiMaso, and R. Löbenberg Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products Eur. J. Pharm. Biopharm. 72 2009 91 98
153. K.S. Pang, L. Liu, and H. Sun Interaction of drug transporters with excipients K.M. Wasan, Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery 2006 John Wiley & Sons, Inc. 1 31
154. D.V. Patel, and E.M. Gordon Applications of small-molecule combinatorial chemistry to drug discovery Drug Discovery Today 1 1996 134 144 (Pubitemid 126402198)
155. M. Perez de la Cruz Moreno, M. Oth, S. Deferme, F. Lammert, J. Tack, J. Dressman, and P. Augustijns Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum J. Pharm. Pharmacol. 58 2006 1079 1089 (Pubitemid 44213641)
156. Pharmacopeial Forum, 1988. Stimuli to the Revision Process: In Vitro/In vivo Correlation for Extended Release Dosage Forms.
157. PMA Joint Committee on Bioavailability, 1985. The Role of Dissolution Testing in Drug Quality, Bioavailability, and Bioequivalence Testing - NeLM, Pharmaceutical Technology.
158. J.E. Polli In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms AAPS J. 10 2008 289 299
159. C.S. Polster, F. Atassi, S.-J. Wu, and D.C. Sperry Use of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variability Mol. Pharm. 7 2010 1533 1538
160. C.J.H. Porter, A.M. Kaukonen, B.J. Boyd, G.A. Edwards, and W.N. Charman Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation Pharm. Res. 21 2004 1405 1412 (Pubitemid 39149655)
161. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248 (Pubitemid 46344627)
162. ProDigest - Gastrointestinal Expertise, 2013. < http://www.prodigest. eu/en/home >.
163. D. Psachoulias, M. Vertzoni, J. Butler, D. Busby, M. Symillides, J. Dressman, and C. Reppas An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine Pharm. Res. 29 2012 3486 3498
164. Y. Qiu, Y. Chen, G.G.Z. Zhang, L. Liu, and W. Porter Developing Solid Oral Dosage Forms: Pharmaceutical Theory & Practice 2009 Academic Press
165. A. Radwan, G.L. Amidon, and P. Langguth Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity Biopharm. Drug Dispos. 33 2012 403 416
166. B. Ramos Pezzini, and H. Gomes Ferraz Bio-dis and the paddle dissolution apparatuses applied to the release characterization of ketoprofen from hypromellose matrices AAPS PharmSciTech 10 2009 763 771
167. P.M. Reis, T.W. Raab, J.Y. Chuat, M.E. Leser, R. Miller, H.J. Watzke, and K. Holmberg Influence of surfactants on lipase fat digestion in a model gastro-intestinal system Food Biophys. 3 2008 370 381
168. B.R. Rohrs, D.L. Burch-Clark, M.J. Witt, and D.J. Stelzer USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations J. Pharm. Sci. 84 1995 922 926
169. M.J. Roman, B.J. Burri, and R.P. Singh Release and bioaccessibility of β-carotene from fortified almond butter during in vitro digestion J. Agric. Food Chem. 60 2012 9659 9666
170. A. Rostami-Hodjegan, M.R. Shiran, R. Ayesh, T.J. Grattan, I. Burnett, A. Darby-Dowman, and G.T. Tucker A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. I. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers Drug Dev. Ind. Pharm. 28 2002 523 531 (Pubitemid 34680552)
171. A. Rostami-Hodjegan, M.R. Shiran, G.T. Tucker, B.R. Conway, W.J. Irwin, L.R. Shaw, and T.J. Grattan A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation Drug Dev. Ind. Pharm. 28 2002 533 543 (Pubitemid 34680553)
172. T. Rygnestad, K. Zahlsen, and F.A. Samdal Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers Eur. J. Clin. Pharmacol. 56 2000 141 143 (Pubitemid 30341388)
173. A. Sandberg, B. Abrahamsson, and J. Sjörgen Influence of dissolution rate on the extent and rate of bioavailability of metoprolol Int. J. Pharm. 1-3 1991 167 177
174. P.J. Sassene, M.M. Knopp, J.Z. Hesselkilde, V. Koradia, A. Larsen, T. Rades, and A. Müllertz Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate J. Pharm. Sci. 99 2010 4982 4991
175. C. Schiller, C.-P. Fröhlich, T. Giessmann, W. Siegmund, H. Mönnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 22 2005 971 979 (Pubitemid 41634879)
176. A. Scholz, B. Abrahamsson, S.M. Diebold, E. Kostewicz, B.I. Polentarutti, A.-L. Ungell, and J.B. Dressman Influence of hydrodynamics and particle size on the absorption of felodipine in labradors Pharm. Res. 19 2002 42 46 (Pubitemid 34075105)
177. A. Scholz, E. Kostewicz, B. Abrahamsson, and J.B. Dressman Can the USP paddle method be used to represent in-vivo hydrodynamics? J. Pharm. Pharmacol. 55 2003 443 451 (Pubitemid 36603262)
178. V.P. Shah, M. Gurbarg, A. Noory, S. Dighe, and J.P. Skelly Influence of higher rates of agitation on release patterns of immediate-release drug products J. Pharm. Sci. 81 1992 500 503
179. M. Shameem, N. Katori, N. Aoyagi, and S. Kojima Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans Pharm. Res. 12 1995 1049 1054
180. T.R. Shaw, K. Raymond, M.R. Howard, and J. Hamer Therapeutic non-equivalence of digoxin tablets in the United Kingdom: correlation with tablet dissolution rate Br. Med. J. 4 1973 763 766
181. L.B. Sheiner Learning versus confirming in clinical drug development Clin. Pharmacol. Ther. 61 1997 275 291 (Pubitemid 27145429)
182. J.J. Sheng, P.J. Sirois, J.B. Dressman, and G.L. Amidon Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed J. Pharm. Sci. 97 2008 4815 4829
183. Y. Shi, P. Gao, Y. Gong, and H. Ping Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption Mol. Pharm. 7 2010 1458 1465
184. G. Shiko, L.F. Gladden, A.J. Sederman, P.C. Connolly, and J.M. Butler MRI studies of the hydrodynamics in a USP 4 dissolution testing cell J. Pharm. Sci. 100 2011 976 991
185. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, and J.B. Dressman Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 73 2009 107 114
186. J.P. Skelley, G.L. Amidon, W.H. Barr, L.Z. Benet, J.E. Carter, J.R. Robinson, V.P. Shah, and A. Yacobi Report of the workshop on in vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms J. Pharm. Sci. 79 1990 849 854 (Pubitemid 20309002)
187. S. Souliman, S. Blanquet, E. Beyssac, and J.-M. Cardot A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form Eur. J. Pharm. Sci. 27 2006 72 79 (Pubitemid 41728257)
188. S. Souliman, E. Beyssac, J.-M. Cardot, S. Denis, and M. Alric Investigation of the biopharmaceutical behavior of theophylline hydrophilic matrix tablets using USP methods and an artificial digestive system Drug Dev. Ind. Pharm. 33 2007 475 483 (Pubitemid 46808777)
189. M. Sugawara, S. Kadomura, X. He, Y. Takekuma, N. Kohri, and K. Miyazaki The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations Eur. J. Pharm. Sci. 26 2005 1 8 (Pubitemid 41097255)
190. V.H. Sunesen, B.L. Pedersen, H.G. Kristensen, and A. Müllertz In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media Eur. J. Pharm. Sci. 24 2005 305 313 (Pubitemid 40283513)
191. R. Takano, N. Takata, R. Saito, K. Furumoto, S. Higo, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Quantitative analysis of the effect of supersaturation on in vivo drug absorption Mol. Pharm. 7 2010 1431 1440
192. R. Takano, M. Kataoka, and S. Yamashita Integrating drug permeability with dissolution profile to develop IVIVC Biopharm. Drug Dispos. 33 2012 354 365
193. C. Tannergren, A. Bergendal, H. Lennernäs, and B. Abrahamsson Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment Mol. Pharm. 6 2009 60 73
194. S. Tenjarla, V. Romasanta, E. Zeijdner, R. Villa, and L. Moro Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system Adv. Ther. 24 2007 826 840 (Pubitemid 351612256)
195. The European Pharmacopoeia, 2011. European Directorate for the Quality of Medicines and HealthCare, Council of Europe, seventh ed. Strasbourg, France.
196. The United States Pharmacopeial Convention, Inc., 2013. The United States Pharmacopeia - The National Formulary. USP 30/NF 25, Rockville, MD.
197. N. Thomas, R. Holm, A. Müllertz, and T. Rades In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) J. Control. Release 160 2012 25 32
198. N. Thomas, R. Holm, T. Rades, and A. Müllertz Characterising lipid lipolysis and its implication in lipid-based formulation development AAPS J. 14 2012 860 871
199. P. Thybo, B.L. Pedersen, L. Hovgaard, R. Holm, and A. Mullertz Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30 Pharm. Dev. Technol. 13 2008 375 386
200. H. Tønsberg, R. Holm, J. Bisgaard, J. Jacobsen, and A. Müllertz Effects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats J. Pharm. Pharmacol. 62 2010 63 70
201. United States Pharmacopoeia Convention, 2012. United States Pharmacopoeia 35 - National, Formulary 30.
202. US Pharmacopoeia, 1990. U.S. Pharmacopoeia National Formulary 1990: USP 21 NF 17.
203. US Pharmacopoeia, 1995. U.S. Pharmacopoeia National Formulary 1995: USP 23 NF 18.
204. US Pharmacopoeia, 2011. U.S. Pharmacopoeia National Formulary 2011: USP 34 NF 29.
205. M. Van Speybroeck, R. Mols, R. Mellaerts, T.D. Thi, J.A. Martens, J. Van Humbeeck, P. Annaert, G. Van den Mooter, and P. Augustijns Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole Eur. J. Pharm. Biopharm. 75 2010 354 365
206. M. Vardakou, A. Mercuri, S.A. Barker, D.Q.M. Craig, R.M. Faulks, and M.S.J. Wickham Achieving antral grinding forces in biorelevant in vitro models: comparing the USP dissolution apparatus II and the dynamic gastric model with human in vivo data AAPS PharmSciTech 12 2011 620 626
207. M. Vardakou, A. Mercuri, T.A. Naylor, D. Rizzo, J.M. Butler, P.C. Connolly, M.S.J. Wickham, and R.M. Faulks Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model Int. J. Pharm. 419 2011 192 199
208. J. Vatier, A. Harman, N. Castela, M.T. Droy-Lefaix, and R. Farinotti Interactions of cimetidine and ranitidine with aluminum-containing antacids and a clay-containing gastric-protective drug in an "artificial stomach-duodenum" model J. Pharm. Sci. 83 1994 962 966 (Pubitemid 24228545)
209. J. Vatier, C. Célice-Pingaud, and R. Farinotti A computerized artificial stomach model to assess sodium alginate-induced pH gradient Int. J. Pharm. 163 1998 225 229 (Pubitemid 28162636)
210. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417 (Pubitemid 40922839)
211. Vertzoni, M., Iliadis, A., Nicolaides, E., Symillides, M., Reppas, C., 2006. In: Dressman J.B., Kraemer J. (Eds.), Orally Administered Drug Products: Dissolution Data Analysis with a View to IVIVC in Pharmaceutical Dissolution Testing, New York, USA, pp. 229-249.
212. M. Vertzoni, A. Diakidou, M. Chatzilias, E. Söderlind, B. Abrahamsson, J.B. Dressman, and C. Reppas Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility Pharm. Res. 27 2010 2187 2196
213. M. Vertzoni, C. Markopoulos, M. Symillides, C. Goumas, G. Imanidis, and C. Reppas Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers Mol. Pharm. 9 2012 1189 1198
214. M. Verwei, K. Arkbåge, R. Havenaar, H. van den Berg, C. Witthöft, and G. Schaafsma Folic acid and 5-methyltetrahydrofolate in fortified milk are bioaccessible as determined in a dynamic in vitro gastrointestinal model J. Nutr. 133 2003 2377 2383 (Pubitemid 36841568)
215. M. Verwei, A.P. Freidig, R. Havenaar, and J.P. Groten Predicted serum folate concentrations based on in vitro studies and kinetic modeling are consistent with measured folate concentrations in humans J. Nutr. 136 2006 3074 3078 (Pubitemid 44878575)
216. M. Vieth, M.G. Siegel, R.E. Higgs, I.A. Watson, D.H. Robertson, K.A. Savin, G.L. Durst, and P.A. Hipskind Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 47 2004 224 232 (Pubitemid 38040506)
217. H. Wei, and R. Löbenberg Biorelevant dissolution media as a predictive tool for glyburide a class II drug Eur. J. Pharm. Sci. 29 2006 45 52 (Pubitemid 44279396)
218. W. Weitschies, M. Karaus, D. Cordini, L. Trahms, J. Breitkreutz, and W. Semmler Magnetic marker monitoring of disintegrating capsules Eur. J. Pharm. Sci. 13 2001 411 416 (Pubitemid 32611599)
219. W. Weitschies, R.-S. Wedemeyer, O. Kosch, K. Fach, S. Nagel, E. Söderlind, L. Trahms, B. Abrahamsson, and H. Mönnikes Impact of the intragastric location of extended release tablets on food interactions J. Control. Release 108 2005 375 385 (Pubitemid 41608669)
220. W. Weitschies, C. Friedrich, R.S. Wedemeyer, M. Schmidtmann, O. Kosch, M. Kinzig, L. Trahms, F. Sörgel, W. Siegmund, S. Horkovics-Kovats, F. Schwarz, J. Raneburger, and H. Mönnikes Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying Eur. J. Pharm. Biopharm. 70 2008 641 648
221. Welling, P.G., Tse, F.L.S., Dighe, S.V., 1991. Pharmaceutical bioequivalence. In: Welling, Peter G., Tse, Francis L.S., Dighe, Shrikant V. (Eds.), Drugs and the Pharmaceutical Sciences, vol. 48. Dekker, New York.
222. M. Wickham, R. Faulks, and C. Mills In vitro digestion methods for assessing the effect of food structure on allergen breakdown Mol. Nutr. Food Res. 53 2009 952 958
223. Faulks Wickham, and Mandalari Mann The design, operation, and application of a dynamic gastric model Dissolut. Technol. 2012 15 22
224. H.D. Williams, M.U. Anby, P. Sassene, K. Kleberg, J.-C. Bakala-N'Goma, M. Calderone, V. Jannin, A. Igonin, A. Partheil, D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, H. Benameur, F. Carrière, A. Müllertz, C.W. Pouton, and C.J.H. Porter Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion Mol. Pharm. 9 2012 3286 3300
225. H.D. Williams, P. Sassene, K. Kleberg, J.-C. Bakala-N'Goma, M. Calderone, V. Jannin, A. Igonin, A. Partheil, D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, H. Benameur, F. Carrière, A. Müllertz, C.J.H. Porter, and C.W. Pouton Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations J. Pharm. Sci. 101 2012 3360 3380
226. H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, and C.J.H. Porter Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 65 2013 315 499
227. Y. Wu, D.O. Kildsig, and E.S. Ghaly Effect of hydrodynamic environment on tablets dissolution rate Pharm. Dev. Technol. 9 2004 25 37 (Pubitemid 38250224)
228. M. Wulff-Pérez, J. de Vicente, A. Martín-Rodríguez, and M.J. Gálvez-Ruiz Controlling lipolysis through steric surfactants: new insights on the controlled degradation of submicron emulsions after oral and intravenous administration Int. J. Pharm. 423 2012 161 166
229. K. Yano, Y. Masaoka, M. Kataoka, S. Sakuma, and S. Yamashita Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes J. Pharm. Sci. 99 2010 1336 1345
230. Y.Y. Yeap, N.L. Trevaskis, T. Quach, P. Tso, W.N. Charman, and C.J. Porter Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation Mol. Pharm. 10 2013 1874 1889
231. L.X. Yu Pharmaceutical quality by design: product and process development, understanding, and control Pharm. Res. 25 2008 781 791
232. N.H. Zangenberg, A. Müllertz, H.G. Kristensen, and L. Hovgaard A dynamic in vitro lipolysis model. II: evaluation of the model Eur. J. Pharm. Sci. 14 2001 237 244 (Pubitemid 32884320)